Replies to post #48757 on Biotech Values

[atout]

Looks like halted.

[DewDiligence]

COLY – Program-Survival Bias Strikes Again
PF-3512676 phase-2 data from COLY (left)
and the same data (less hyped) from PFE (right).

[DewDiligence]

COLY – The wording of today’s PR (#msg-20613423) and the comments on today’s CC leave the door open a crack for PFE to continue the phase-2 trial testing PF-3512676 with Tarceva in second-line NSCLC. PFE may still be deciding what to do about this trial, which does not employ chemotherapy and hence has a somewhat different risk/benefit tradeoff than all of the other PF-3512676 trials in NSCLC.